AngioDynamics, Inc.

Coverage News for Irreversible Electroporation (IRE)! 🎉 Humana Medicare Advantage has updated its coverage policy for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System*, effective October 1, 2026. The policy applies Medicare LCD medical necessity criteria across MAC jurisdictions, using L40205 where no other LCD applies. This is an important step toward more consistent access to IRE for eligible patients. With approximately 7 million Medicare Advantage members, this represents another significant reimbursement milestone for IRE. The updated policy builds on continued reimbursement progress, including the establishment of Category I CPT® codes 55877 for prostate tissue ablation and 47384 for liver tumor ablation, and Palmetto GBA’s final LCD L40205. For physicians treating appropriately selected patients with favorable intermediate-risk prostate cancer (Grade Group 2 (Gleason Score 3+4)) and metastatic colorectal cancer to the liver, this policy supports a more consistent framework for determining coverage across MAC jurisdictions. Another meaningful step forward in expanding access to IRE for the patients and physicians we serve! Read the full announcement: bwnews.pr/4BeuYdD *Coverage remains subject to Humana’s prior authorization process and the terms of each member’s plan. #NanoKnife #IrreversibleElectroporation #ProstateCancer #MedicareAdvantage #Reimbursement Risk Info: bit.ly/3UFe4Rf *The NanoKnife System has not received clearance for the therapy or treatment of any specific disease or condition.

Our team in Queensbury, NY had the privilege of hearing from someone whose life was directly impacted by the work they do every day. Sandy, a NanoKnife System patient, joined our annual employee cookout to share her story. Just a short drive from where our devices are manufactured, she reminded us that the products leaving our facility don't just ship around the world. They change lives in our own backyard. For many of our manufacturing team members, their role is focused on precision, quality, and craftsmanship. Hearing firsthand from a patient whose life has been impacted by that work brings a powerful perspective to every device they build. At AngioDynamics, innovation isn't just about advancing technology. It's about the people behind it, and the patients whose lives they touch. Thank you, Sandy, for sharing your journey and reminding all of us why every detail matters. The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. The NanoKnife System has not received clearance for the therapy or treatment of any specific disease or condition. #AngioDynamics #NanoKnife #PatientImpact #Manufacturing #MedTech #PurposeDriven